CROSSLEND
12.10.2021 11:26:13 CEST | Business Wire | Press release
Berlin-based FinTech CrossLend has issued a note to facilitate an investment into lease contracts for bicycles. The transaction is the result of a collaboration between Bikeleasing - the fastest growing e-bike leasing provider, MEAG as asset manager, ERGO as investor, and CrossLend as the structurer and operator of the digital register. Scope rated the note as investment grade and confirmed the ecological impact of the issued note is in accordance with the ICMA Green Bond Principles as part of a second party opinion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211012005499/en/
The transaction reflects several market trends. The goals of a climate-neutral society require substantial investments to replace goods such as cars or heating devices which, in their normal lifespan, would still have years of operation ahead of them. At the same time, cost-intensive innovative products are being offered as part of convenient pay-as-you-go models which contain a lending product and require refinancing. As a result, highly innovative originators such as Bikeleasing are entering into an origination model in competition with banks, or even closing gaps where traditional banking products are not covering the needs of customers. The kinetics in terms of origination frequency, and the level of fragmentation seen in the single tickets of such originations, require a digital and data-driven transactional link to traditional capital market investors. Accordingly, CrossLend structured and issued a note on its digital asset register which complied with the ICMA Green Bond Principles.
"The transformation of the economy and society towards climate-friendly technologies requires unparalleled investments in a relatively short period of time. The reality is that non-digital investment banking cannot keep up with the kinetics of innovative product providers such as Bikeleasing. We are extremely proud that our digital asset technology closes a gap between agile, transformative products and the capital markets, enabling established institutions like MEAG and ERGO to conveniently invest to support ecological change," says Oliver Schimek, Chief Executive Officer of CrossLend GmbH.
According to Thomas Bayerl, Head of Illiquid Assets Debt at MEAG: "As an asset manager, we work in an environment where digital transformation and sustainability criteria play an increasing role in the development of investable assets. CrossLend's digital asset platform and register were instrumental in making this asset accessible for our client ERGO today. This transaction can serve as a successful example for further implementation possibilities in a variety of industries."
Paul Sinizin, co-founder and CEO of Bikeleasing comments: "Bikeleasing has been growing extremely fast and we still see a large untapped market opportunity ahead. For our growth we require a flexible and scalable funding source. Working with a technology platform like CrossLend allows us to minimise our operational efforts on the capital markets activity through automation and industrialisation."
About CrossLend
CrossLend is a FinTech company that provides full spectrum technology for loan asset transactions. Its mission is to make the world's lending and investment ecosystem more efficient, transparent, and profitable. Supervised by BaFIN and CSSF, CrossLend is backed by an array of prestigious equity investors from Europe and the US, including Mouro Capital (formerly Santander InnoVentures), Lakestar, CME Ventures, Earlybird, ABN AMRO's Digital Impact Fund, and the Luxembourg Future Fund (EIF and SNCI).
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005499/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 10:00:00 CEST | Press release
Gabriele Salvatores, together with Rob Minkoff, Catherine Hardwicke, Jed Weintrob, Christina Lee Storm, Nils Hartmann, Guillem Martinez Roura, Filippo Rizzante, Giacomo Mineo, Brian Welk and Denise Negri, will judge the short films in competition based on creativity, production quality and the use of Artificial Intelligence. Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, wh
Bregal Milestone Announces Majority Growth Investment in CoreGo, a Leading European Open-Loop Payment and Event Technology Company29.4.2026 10:00:00 CEST | Press release
Investment follows over 98% annual growth and supports CoreGo’s continued market expansion Bregal Milestone, a leading European software growth private equity firm, today announced a majority strategic growth investment in CoreGo Oy ("CoreGo" or the "Company"), a leading provider of open-loop payments and integrated technology solutions for festivals, sports events, and venues across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427991105/en/ Founded in Helsinki in 2015 by Hannu Elomaa and CTO Nikoteemu Väänänen, CoreGo has built one of Europe's most differentiated open-loop payment infrastructure and event technology businesses. Serving approximately 250 customers across the Nordics and DACH region, the Company delivers an integrated showtime-critical suite of solutions through CoreGo Cloud, unifying payments, access, networks, and data into a single real-time operating system. CoreGo’s in-house private network
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
